All rights reserved. No reuse allowed without permission.

1 Cross-ancestral GWAS identifies 29 novel variants across Head and Neck Cancer 2 subsites

3

Ebrahimi E^{1,2}. Sanaphukieo A^{1,3}. Park HA¹. Gaborieau V¹. Ferreiro-Iglesias A¹. Diergaarde B⁴. 4 Ahrens W⁵, Alemany L^{6,7,8}, Arantes LMRB⁹, Betka J¹⁰, Bratman SV¹¹, Canova C¹², Conlon 5 MSC¹³, Conway DI¹⁴, Cuello M¹⁵, Curado M¹⁶, de Carvalho A¹, de Oliviera J¹⁷, Gormley M¹⁸, 6 Hadji M^{2,19}, Hargreaves S²⁰, Healy CM²¹, Holcatova I²², Hung RJ^{23,24}, Kowalski LP^{25,26}, Lagiou 7 P²⁷, Lagiou A²⁸, Liu G²⁹, Macfarlane GJ³⁰, Olshan AF³¹, Perdomo S¹, Pinto LF³², Podesta JV³³, 8 Polesel J³⁴, Pring M¹⁸, Rashidian H², Gama RR³⁵, Richiardi L³⁶, Robinson M³⁷, Rodriguez-9 Urrego PA³⁸, Santi SA³⁹, Saunders DP⁴⁰, Soares-Lima SC⁴¹, Timpson N⁴², Vilensky M⁴³, von 10 Zeidler SV⁴⁴, Waterboer T⁴⁵, Zendehdel K², Znaor A⁴⁶, Brennan P¹, HEADSpAcE 11 12 Consortium⁴⁷, McKay J¹, Virani S^{1*}, Dudding T^{18*}.

13

14 *Co-last, co-corresponding authors

- 15 *Shama Virani
- 16 <u>viranis@iarc.who.int</u> 17
- 18 *Tom Dudding
- 19 tom.dudding@bristol.ac.uk

20 ¹Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France, 21 ²Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran, ³Center of 22 Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, 23 Chiang Mai, Thailand, ⁴Department of Human Genetics, School of Public Health, University of Pittsburgh, and 24 UPMC Hillman Cancer Center, Pittsburgh, USA, ⁵Leibniz Institute for Prevention Research and Epidemiology-25 BIPS, Bremen, Germany, ⁶Catalan Institute of Oncology. ICO, L'Hospitalet, Barcelona, Spain, ⁷Bellvitge Biomedical 26 Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain, 8CIBER en Epidemiología y Salud Pública 27 (CIBERESP), Madrid, Spain, ⁹Barretos Cancer Hospital, Barretos, Brazil, ¹⁰Department of Otorhinolarygology and 28 Head And Neck Surgery, 1.st Medical Faculty, Charles University, Faculty Hospital Motol, Prague, Czech Republic, 29 ¹¹Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada, 30 ¹²Unit of Biostatistics, Epidemiology and Public Health, Department of Cardio-Thoraco-Vascular Sciences and 31 Public Health, University of Padova, Padova, Italy, ¹³Epidemiology, Outcomes & Evaluation Research, Health 32 Sciences North Research Institute, Sudbury, Canada, ¹⁴School of Medicine, Dentistry and Nursing, University of 33 Glasgow, Glasgow, UK, ¹⁵Oncology, Hospital de Clinicas Dr. Manuel Quintela, Montevideo, Uruguay, 34 ¹⁶Epidemiology and Statistics Group, Research Center, A.C Camargo Cancer Center, São Paulo, Brazil, ¹⁷Araújo 35 Jorge Cancer Hospital, Associação de Combate ao Câncer em Goiás, Goiania, Brazil, ¹⁸Bristol Dental School, 36 Bristol University, Bristol, UK, ¹⁹A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 37 Finland, ²⁰University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK, ²¹School of Dental Science, 38 Dublin Dental University Hospital, Trinity College Dublin, Dublin, Ireland, ²²Institute of Hygiene & Epidemiology, 1st 39 Faculty of Medicine, Charles University, Prague, Czech Republic, ²³Prosserman Centre for Population Health 40 Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada, ²⁴Division of 41 Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada, ²⁵Department of Head 42 and Neck Surgery, University of São Paulo Medical School, São Paulo, Brazil, ²⁶Department of Head and Neck

All rights reserved. No reuse allowed without permission.

43 Surgery and Otorhinolaryngology, A C Camargo Cancer Center, São Paulo, Brazil, ²⁷Department of Hygiene, 44 Epidemiology & Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, 45 Greece, ²⁸Department of Public and Community Health, School of Public Health, University of West Attica, Athens, 46 Greece, ²⁹Medicine, Epidemiology, Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, 47 Toronto, Canada, ³⁰Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of 48 Aberdeen, Aberdeen, UK, ³¹Department of Epidemiology, Gillings School of Global Public Health, University of 49 North Carolina, Chapel Hill, USA, ³²Programa de Carcinogênese Molecular, Instituto Nacional de Câncer - INCA, 50 Rio de Janeiro, Brazil, ³³Head and Neck Surgery Division, Women's Association for Education and Fight Against 51 Cancer/AFECC, Vitória, Brazil, ³⁴Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) 52 IRCCS, Aviano, Italy, ³⁵Department of Head and Neck Surgery, Barretos Cancer Hospital, São Paulo, Brazil, 53 ³⁶Cancer Epidemiology Unit, University of Turin, Turin, Italy, ³⁷Cellular Pathology, The Newcastle upon Tyne 54 Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK, ³⁸Pathology and Laboratories, Pathology, University 55 Hospital Fundacion Santa Fe de Bogota, Bogota, Colombia, ³⁹Clinical Oncology Research, Health Sciences North 56 Research Institute, Sudbury, Canada, ⁴⁰Department of Dental Oncology, Health Sciences North, Northern Ontario 57 School of Medicine University, Sudbury, Canada, ⁴¹Brazilian National Cancer Institute, Rio de Janeiro, Brazil, 58 ⁴²MRC Integrative Epidemiology Unit, Bristol University, Bristol, UK, ⁴³Instituto de Oncologia Angel H Roffo, 59 Universidad de Buenos Aires, Buenos Aires, Argentina, ⁴⁴Pathology Department, Federal University of Espírito 60 Santo, Vitória, Brazil, ⁴⁵Infections and Cancer Epidemiology, German Cancer Research Center (Deutsches 61 Krebsforschungszentrum, DKFZ), Heidelberg, Germany, ⁴⁶Cancer Surveillance Branch, International Agency for 62 Research on Cancer (IARC/WHO), Lyon, France, ⁴⁷A list of authors and their affiliations appears at the end of the 63 paper.

64

65 Acknowledgements and funding:

This study was funded in part by the European Union's Horizon 2020 research and innovation program under grant agreement No 825771 (HEADSpAcE project) and by the US National Institute of Dental and Craniofacial Research (NIDCR) grants R03DE030257 and R01DE025712. Genotyping using the Oncoarray and the All of Us array was performed at Center for Inherited Disease (CIDR) and funded by NIDCR 1X01HG007780-0 and jointly by NIDCR/NCI X01HG010743.

72 This publication presents data from the Head and Neck 5000 study. The study was a 73 component of independent research funded by the National Institute for Health and Care 74 Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-75 10034). The views expressed in this publication are those of the author(s) and not necessarily 76 those of the NHS, the NIHR or the Department of Health. Core funding was also provided 77 through awards from Above and Beyond, University Hospitals Bristol and Weston Research 78 Capability Funding and the NIHR Senior Investigator award to Professor Andy Ness. Round 79 1 genotyping was funded by US National Institute of Dental and Craniofacial Research 80 (NIDCR) grant 1X01HG007780-0. Round 2 genotyping was funded by World Cancer

Research Fund Pilot Grant (grant number: 2018/1792), Above and Beyond Charity (GA2500),
Wellcome Trust Research Training Fellowship (201237/Z/16/Z) and Cancer Research UK
Programme Grant, the Integrative Cancer Epidemiology Programme (grant number:
C18281/A19169). This latter grant also supported Human papillomavirus (HPV) serology. This
research has been conducted using the UK Biobank Resource under Application Number
40644. The work of Dr. Polesel is partially supported by Italian Ministry of Health 'Ricerca
Corrente'.

- The University of Pittsburgh head and neck cancer case-control study is supported by US
 National Institutes of Health grants P50CA097190, P30CA047904 and R01DE025712.
- 90 Geoffrey Liu is the M. Qasim Choksi Research Chair in Translational Research at University
- 91 Health Network and University of Toronto and is supported by the Princess Margaret Head
- and Neck Translational Program, which is supported by philanthropic funds from the Wharton
- 93 Family, Joe's Team, Gordon Tozer, Reed Fund, and the Riley Family.
- 94 The University of North Carolina studies were supported in part by grants CA61188 and95 CA90731 from the National Institutes of Health.
- 96 Northern Cancer Foundation (Principal Investigator Grants to MSC Conlon, DP Saunders).
- Rayjean J. Hung is the CIHR Canada Research Chair and the study is supported by theCanadian Cancer Society and Canadian Institute of Health Research.
- 99 The authors would like to thank all the patients, and their families involved in these studies.
- Where members are identified as personnel of the International Agency for Research on Cancer/ World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.

104 **Conflict of Interest Disclosure:**

- 105 Tim Waterboer serves on advisory boards for MSD (Merck) Sharp & Dohme.
- 106 Scott V Bratman is inventor on patents related to cell-free DNA mutation and methylation
- 107 analysis technologies that are unrelated to this work and have been licensed to Roche and
- 108 Adela, respectively. Scott V Bratman is a co-founder of and has ownership in Adela.

All rights reserved. No reuse allowed without perm

109 Abstract (192 words)

In this multi-ancestry genome-wide association study (GWAS) and fine mapping study of head 110 111 and neck squamous cell carcinoma (HNSCC) subsites, we analysed 19,073 cases and 38,857 112 controls and identified 29 independent novel loci. We provide robust evidence that a 3' UTR 113 variant in TP53 (rs78378222, T>G) confers a 40% reduction in odds of developing overall 114 HNSCC. We further examine the gene-environment relationship of BRCA2 and ADH1B 115 variants demonstrating their effects act through both smoking and alcohol use. Through 116 analyses focused on the human leukocyte antigen (HLA) region, we highlight that although 117 human papilloma virus (HPV)(+) oropharyngeal cancer (OPC), HPV(-) OPC and oral cavity cancer (OC) all show GWAS signal at 6p21, each subsite has distinct associations at the 118 119 variant, amino acid, and 4-digit allele level. We also defined the specific amino acid changes 120 underlying the well-known DRB1*13:01-DQA1*01:03-DQB1*06:03 protective haplotype for 121 HPV(+) OPC. We show greater heritability of HPV(+) OPC compared to other subsites, likely 122 to be explained by HLA effects. These findings advance our understanding of the genetic 123 architecture of head and neck squamous cell carcinoma, providing important insights into the 124 role of genetic variation across ancestries, tumor subsites, and gene-environment interactions.

125 Main

126 Head and neck squamous cell carcinomas (HNSCC) are a heterogeneous group of cancers 127 originating primarily in the oral cavity (OC), oropharynx (OPC), larynx (LA) and hypopharynx 128 (HPC). Currently, HNSCC is ranked the 6th most common cancer globally, although incidence is predicted to increase 30% by 2030^{1,2}. Tobacco smoking and alcohol consumption are major 129 130 risk factors, particularly in high income countries, contributing to 72% of cases when used 131 together, while betel guid/areca nut products significantly increase risk in some Asia-Pacific 132 populations². HNSCC subsites can be differentially affected, with smoking more strongly 133 linked to laryngeal cancer and drinking more strongly linked to OC/OPC³. There has been a 134 decline in smoking in high income countries, as such, the increasing incidence could be due 135 to changes in etiology⁴. Infection with human papillomavirus (HPV), particularly HPV type 16, is a recently identified causal risk factor for OPC⁵⁻⁷ and the proportion of HPV-associated 136 137 OPCs is highest in high-income countries (63%-85%)⁸. Disparities in epidemiology, risk, and 138 prognosis highlight the recognition of HPV-associated OPC as a distinct biological entity⁹.

Although a limited number of genome-wide association studies (GWAS) have been conducted
on HNSCC, a germline contribution to HNSCC risk has been established, with multiple
susceptibility loci associated with risk. These include the 4q23 locus (*ADH1B, ADH7*) linked
to genes involved in alcohol metabolism, the 5p15 locus (*TERT-CLPTM1L*) associated with

genes responsible for DNA stability maintenance, and the 6p21 and 6p22 loci, mostly within
the human leukocyte antigen (HLA) region, corresponding with genes regulating the innate

immune response ^{10–14}. The 6p locus within the HLA region has been a specific area of focus 145 146 for HPV-driven cancers, with the hypothesis being that variants influencing immune response to viral antigens would be most relevant for risk^{10,13,14}. However, there is an emerging role for 147 the immune microenvironment for other HNSCC subsites¹⁵, suggesting that the HLA may 148 149 confer risk separately in other HNSCC subsites, potentially via non-HPV mechanisms. 150 Previous GWAS were limited in sample size for HNSCC subsites making inference between 151 subsites, particularly for HLA, difficult. They were also conducted predominantly in subjects of 152 European ancestry, limiting generalizability of findings.

153 Despite knowledge of the major risk factors and several risk loci for HNSCC, identifying those 154 who will develop cancer is still difficult. Not all smokers develop cancer and risk loci only offer 155 a fractional change in risk at the population level. The interaction between environmental 156 factors and risk loci may help explain additional risk and have been reported for lung cancer (smoking)¹⁶, colorectal cancer (alcohol)¹⁷ and bladder cancer (arsenic exposure)¹⁸ among 157 others. Studies investigating these interactions need large sample sizes and individual level 158 159 exposure data harmonised across studies which, is often not possible in large GWAS meta-160 analyses.

Here, we perform a cross-ancestry GWAS of HNSCC using individual level data, bringing together studies from Europe, North America, South America, South Asia and the Middle East. We identify multiple novel genetic risk susceptibility loci, determine shared and unique risk loci across subsites, explore interactions between genetic and environmental factors in HNSCC risk and conduct fine mapping of the HLA region. This work lays the foundation for identifying HNSCC susceptibility loci with increased representation from non-European populations.

167 Results

168 Cross-ancestral meta-analysis identifies 18 novel genetic loci across HNSCC subsites.

In this cross-ancestral meta-analysis of two pooled individual level datasets (Table S1), we
evaluated 13,092,551 genetic variants in 19,073 HNSCC cases and 38,857 controls. Of the
HNSCC cases, there were 5,596 (29%) oral cavity (OC), 5,411 (28%) oropharyngeal (OPC),
4,409 (23%) laryngeal (LA), 898 (5%) hypopharyngeal (HPC), 2,759 (14%) unknown (either
unknown primary site or not available) or overlapping sites. HPV status was available for 68%
of OPC cases, of which 3,685 (60%) were HPV(+) (Table S2).

All rights reserved. No reuse allowed without permission.

We identified 18 novel genome-wide associated variants, including two specific to non-European ancestry (Table 1, Figure 1, Figure S1) and validated 6 previously identified loci (Table S3, S4). A specific focus on the HLA region identified 11 further novel variants. The proportion of variance attributable to genome-wide SNPs for HNSCC overall was 14% (95% Confidence Interval (CI): 12.7, 15.3). Across subsites, heritability ranged from 7.6% (95% CI: 5.0, 10.2) for HPC to 29.1% (95% CI: 25.5, 32.7) for HPV(+) OPC (Table S5).

181 For overall HNSCC, two novel variants in the 1q32 region were identified. rs61817953, near 182 PIK3C2B, was associated with decreased risk (OR (95%CI)=0.90 (0.87, 0.93), p_{meta}= 2.17x10⁻ ⁸) and rs6679311 near *MDM4*, a strong negative regulator of p53, was associated with 183 increased risk (OR (95% CI)=1.11 (1.07, 1.14), p_{meta}=1.25x10⁻¹⁰) (Figure S2). The latter is in 184 moderately high LD (r²=0.75) with rs4245739, an *MDM4* 3' UTR variant known to increase 185 breast¹⁹ and prostate²⁰ cancer risk. At the 13g13 locus, rs7334543, a novel 3' UTR variant in 186 187 BRCA2 was associated with decreased risk of overall HNSCC (OR (95%CI)= 0.91 (0.88, 0.94), p_{meta}=2.39x10⁻⁸) and was independent from rs11571833, stop gain variant previously 188 identified in this region for UADTs¹². Within those of European ancestry, rs78378222 a 3' UTR 189 variant in TP53, was associated with a reduced risk of HNSCC overall, (OR (95% CI)=0.62 190 191 (0.52, 0.73), p=2.16x10⁻⁸) (Figure 2a). The effect was consistent across all non-HPV related 192 HNSCC subtypes but had no effect in HPV(+) OPC. The T>G allele frequency of rs78378222 193 is 0.01 in EUR, 0.002 in AFR and AMR populations, and nearly absent in all other 1000 194 Genomes super-populations; as such, there was no effect of this variant in the Mixed ancestry. 195 Given its low frequency, technical validation was performed in 2,370 samples and 196 concordance with imputed data was 99.9% (Table S6). There was strong evidence for this 197 variant being correlated with decreased gene expression of TP53 (Figure 2b) (Table S7). This 198 variant is in the poly-adenylation signal of the TP53 gene and potentially leads to impaired 3' end processing of *TP53* mRNA²¹. rs78378222 is located within a highly conserved sequence 199 200 (TTTTATTGTAAAATA -> TTGTATTGTAAAATA) that appears to be crucial for miRNA binding. 201 This region is predicted to interact with 5 different microRNAs (miRNAs) as suggested by 202 TarBase (https://dianalab.e-ce.uth.gr/tarbasev9) (Figure 2c).

For OC, three novel loci were identified (Table 1). First, rs28419191, an intergenic variant at 5q31 associated with an increased risk of OC (OR (95% CI)=1.23 (1.15, 1.31), p_{meta} =3.16x10⁻¹⁰). This variant was in high LD with rs1131769 (r²=0.93), a missense variant in *STING1* which was a novel loci for overall HNSCC risk (OR=1.13 (1.09, 1.18), p_{meta} =2.38x10⁻¹⁰) (Table 1, Figure 2d). Both rs28419191 and rs1131769 correlated with expression of catenin alpha 1 (*CTNNA1*), a gene related to RNA and actin filament binding, but not *STING1* expression in whole blood; as such, the function of this variant is unclear (Figure 2e). The second novel

210 variant rs67351073, located at 20g13 in Zinc Finger CCCH-Type And G-Patch Domain 211 Containing (ZGPAT), was associated with reduced risk of OC (OR (95%CI)=0.78 (0.72, 0.85), p_{meta}=4.45x10⁻⁸). A highly correlated variant seen within the European ancestry only 212 213 (rs4809325, r²=0.97), which also decreased OC risk, was correlated with decreased ZGPAT 214 gene expression in whole blood (PP4 score=0.97) and increased LIME1 gene expression in 215 oesophageal and lung mucosa (Figure S3, Table S7). Finally, a novel, rare, European 216 ancestry-specific intronic variant, rs577454702, located in the mitogen-activated protein 217 kinase 1 (MAPK1) gene at 22g11, was associated with a large increased risk of OC (OR (95%CI)=2.60 (1.86, 3.65), p=2.53x10⁻⁸). 218

219 For laryngeal cancer, rs55831773, a novel splice variant, mapping to ATP1B2 was associated 220 with increased risk (OR (95% CI)=1.21 (1.13, 1.29), p_{meta}=5.1x10⁻⁹). ATP1B2 is in close 221 proximity to TP53 but conditional analyses suggest this variant is independent of the rare TP53 222 3' UTR variant described for overall HNSCC. There was also no evidence that rs55831773 223 alters TP53 expression, further suggesting independent effects of these two variants (Figure 224 S4). A novel intronic variant, rs10419397, located in a gene dense region of 19p13 was also strongly associated with LA (OR (95%CI)=1.13 (1.10, 1.17), p_{meta}=1.21x10⁻¹⁴). This variant has 225 been found to associate with mitochondrial dysfunction^{22,23} and is in very high LD with several 226 variants associated with risk of other cancers, including rs4808616 (r²>0.99), a 3' UTR for 227 ABHD8 linked to breast and lung cancers²⁴. rs200410709 is a novel variant which showed 228 229 increased risks in the Mixed ancestry but with no evidence of effect in Europeans. It is a 230 deletion variant in an intergenic region, adjacent to the Syntaxin Binding Protein 6 (STXBP6) 231 gene (14q12), and was associated with increased risk of LA (OR (95% CI)=3.38 (2.26, 5.07), 232 p=3.57x10⁻⁹) (Figure S5).

233 Five HPC specific variants were identified for the first time. rs138707495, a rare (MAF: 234 European = 0.009, Mixed = 0.005) variant located in the 3' UTR of GDF7 (OR (95%CI)=3.06 235 (2.07, 4.53), p_{meta}=2.33x10⁻⁸), rs77750788 at 11q25 near *IGSF9B* (OR (95%CI)=2.07 (1.61, 236 2.68), p_{meta}=2.03x10⁻⁸) and rs181194133 an intronic variant in OPCML (OR (95%CI)= 3.44 (2.24, 5.31), p_{meta} = 2.09x08⁻⁰⁸) were all associated with increased risk of HPC in the cross-237 238 ancestral meta-analysis. Within the European group, rs181777026 (11q14) located near 239 TENM4 was associated with increased risk of HPC. Conversely, rs150899739 (6q24), which showed an increased risk in the Mixed ancestry but no effect in Europeans, is within SASH1 240 and greatly increased the risk for HPC (OR (95% CI)=5.84 (3.17, 10.76), $p=1.47 \times 10^{-8}$) (Figure 241 242 S6).

At 3p21, rs1520483, a novel intronic variant in the lactotransferrin (*LTF*) gene, associated with an increased risk of HPV(+) OPC (OR (95% CI)=1.23 (1.14, 1.32), p=2.19x10⁻⁸) in Europeans. *LTF* acts as a transcription factor, inducing expression of innate immune related genes for antiviral host defence^{25,26}.

rs112726671, a variant near the vitamin D receptor (VDR) gene, was associated with risk of HPV(-) OPC (OR (95%CI)=1.23 (1.14, 1.32), $p_{meta}=2.19x10^{-8}$). This variant is independent from rs35189640, a nearby variant previously identified to increase risk of HPV(-) OPC (r²=0.0005)¹⁰.

251 Refining previously identified HNSCC risk variants

252 Loci identified in previous GWAS of HNSCCs at 4q23 (ADH1B, ADH1C, ADH7), 5p15 253 (CLPTM1L), 6p21 (HLA), 6p22 (ZNRD1-AS1), 9p21 (CDKN2B-AS1), 12q24 (ALDH2) and 254 15q21 (FGF7) were validated here. Notably, rs11571833 (13q13), the rare (MAF: 255 Europeans=0.009, Mixed=0.007) stop gained variant, resulting in a stop codon 93 amino acids 256 early in the BRCA2 protein, was strongly associated with an increased risk of LA (OR (95% CI)=2.09 (1.65, 2.66), p_{meta}=1.57x10⁻⁹) and HPC (lead variant for HPC- rs11571815: OR (95%) 257 CI)=2.73 (1.61, 3.90), p_{meta}=3.99x10⁻⁸) separately. Previous GWAS combining lung and 258 aerodigestive tract cancers as well as studies using targeted genotyping have found this 259 260 variant to substantially increase risk for smoking related cancers²⁷, however this is the first 261 time this variant was identified in within specific subsites.

262 Distinct interactions of smoking and alcohol use with risk variants

263 rs11571833 the BRCA2 stop-gained variant validated here showed clear evidence of a dose-264 response effect across smoking and drinking strata, but the variant did not correlate with 265 variants related to smoking-related behaviours such as smoking initiation or cigarettes per day 266 in colocalization analysis (Table S7). However, the variant effect was present in both nondrinking smokers and non-smoking drinkers, suggesting the risk increasing effect of 267 268 rs11571833 requires either carcinogenic influence. This BRCA2 variant shows a similar gene-269 environment interaction separately within the European and Mixed ancestries, despite 270 differences in sample size (Figure 3a).

We confirm that rs1229984, the well-described missense variant in the *ADH1B* gene, has a strong protective effect on OC which is only seen in smokers or in drinkers when stratifying by use (Figure S6b). However, we measure a strong correlation between rs1229984 and variants associated with alcoholic drinks per week but not cigarettes per day or smoking initiation (Table

S7). To separate out the linked behaviors of smoking and drinking we investigated the association in combinations of drinking and smoking status. These analyses confirm rs1229984 has an effect in those who smoke and drink and in non-drinking smokers but not non-smoking drinkers, suggesting the mechanism through smoking as may be more important (Figure 3b). Interactions with smoking and drinking for *ADH1C* and *ADH7* were less clear.

rs58365910 near *CHRNA5*, known to alter smoking intensity³⁶ showed a suggestive
association with LA consistent effects across the European and Mixed ancestries (Figure S8).
The increasing risk effect of this variant was correlated with increased smoking intensity and
when evaluated by exposure group, this variant shows a clear interaction with smoking but
not alcohol use (Figure 3c).

285 Novel Loci in the HLA Region specific to oral cavity and oropharynx cancer

286 Our genome-wide results highlight heterogeneity in the Human Leukocyte Antigen (HLA) 287 region, which encodes genes involved in immune response, across HNSCC subsites. For 288 HPV(+) OPC, signals were identified at both 6p21 and 6p22 but for OC only the 6p21 signal 289 was seen. The HLA region is particularly susceptible to genetic diversity across populations 290 and is highly polymorphic with a dense LD structure. To account for this, genotyped variants in this region were re-imputed to define variants, amino acid changes and 4-digit alleles, which 291 292 were then analysed separately using fine mapping strategies to identify independent signals. Independence of signals was carefully evaluated using linkage and conditional analysis 293 294 (Tables S8, S9).

Overall, 19 independent signals reached significance (Tables S10, S11). Eleven novel risk
variants were identified specific to OC, HPV(+) OPC, HPV(-) OPC, and for HNSCC overall
(Table 2, Figure S9).

Three novel intronic variants were associated with risk of HNSCC overall. The Chr6:33046667 variant, near *HLA-DPB1* (OR (95% CI)= 1.11 (1.07, 1.14), p_{meta} =1.32x10⁻⁸) and rs28360051 near *PSORS1C3* (OR (95% CI)= 1.23 (1.14, 1.34), p_{meta} =1.91x10⁻⁷) both increased HNSCC risk. The rs28360051 variant was strongly driven by its effect in HPV(+) OPC. A novel intronic variant, rs1536036, mapping to *ITPR3*, a receptor that mediates the release of intracellular calcium, was protective for HNSCC overall (OR (95% CI)= 0.85 (0.80, 0.91), p= 8.42x10⁻⁷) only in the admixed ancestry.

For HPV(+) OPC, five novel variants were identified. rs4143334, in the noncoding transcript exon of *ZDHHC20P2* increased cancer risk (OR (95% CI)= 1.89 (1.51, 2.35), p_{meta} =1.91x10⁻

All rights reserved. No reuse allowed without permission.

⁸). The remaining three had important functional significance. The first (DRB1 37Asn/Ser) 307 308 causes an amino acid change in the antigen binding pocket (P9 pocket) of the beta chain of the HLA-DR protein and reduces HPV(+) OPC risk (OR (95% CI)= 0.68 (0.63, 0.73), pmeta= 309 310 3.22x10⁻²³). The second (HLA-B 67Cys/Ser/Tyr) is in an antigen binding pocket (B-pocket) of 311 HLA-B and also results in decreased HPV(+) OPC risk (OR (95% CI)=0.81 (0.74, 0.88), pmeta= 312 1.33x10⁻⁶) (Figure 4a). The third (DRB1 233Thr), is in exon 5 of DRB1 and increases risk of 313 HPV(+) OPC (OR (95% CI)=1.27 (1.17, 1.38), p_{meta}= 7.15x10⁻⁹). This amino acid change is in 314 high LD with several others that are in the HLA-DR binding pocket, of which 5 have similar 315 risk (Table S12). Accuracy of best-fit models, which included each amino acid in place of 316 DRB1 233Thr, were found to be similar to the original model containing DRB1 233Thr (ABIC ±2), indicating that presence of any of these five amino acid changes-including DRB1 317 318 10Glu/Gln and 12Lys located in the HLA binding pocket—confers similar levels of risk (Figure 319 4b, Table S12). Within those of European ancestry, the novel HLA-B*51:01 allele increased 320 risk of HPV(+) OPC (OR (95% CI)=1.9 (1.55, 2.31), p_{meta}= 3.6x10⁻¹⁰).

For HPV(-) OPC, rs1131212 was found to be associated with an increased risk (OR (95%CI)=1.33 (1.19, 1.49), p_{meta} =5.33x10⁻⁷) (Figure 5a). This novel, functional variant maps to exon 2 of the *HLA-B* gene causing an amino acid change Gln94His in an *HLA-B* binding pocket. rs1131212 tags another functional HLA-B amino acid change, HLA-B 70Asn/Ser (Table S12) in strong LD (r²=1) which has a similar effect and with similar model accuracy (OR (95%CI)=1.32 (1.18, 1.47), p_{meta} =8.81x10⁻⁷) (Figure 5b). These results suggest that presence of either rs1131212 or HLA-B 70Asn/Ser is equivocal to increase cancer risk.

- The novel HLA-A*24 allele tagged the known intronic variant rs1264813 in *MICD*, and was similarly associated with increased risk of HPV(-) OPC (OR (95% CI)= 1.34 (1.18, 1.52), $p_{meta}=7.24x10^{-6}$). Accuracy of the model including this allele was similar to the model including rs1264813, suggesting these signals convey similar risk (Figure 5c, Tables S12).
- 332 A novel haplotype was identified that tagged the known intronic variant, rs9268925 in DRB9, 333 and was associated with decreased risk of OC (OR (95% CI)= 0.8 (0.73, 0.86), pmeta= 2.15x10⁻ 334 ⁸). The haplotype, DRB1*15:01-DQA1*01:02-DQB1*06:02, had a similar risk and similar 335 model accuracy compared to the known variant, suggesting that this variant and the novel 336 haplotype can be used interchangeable to measure this risk (Figure 5d). Two novel variants 337 specific to the European ancestry were associated with risk of OC: DRB1 74Ala/Leu/Del (OR (95% CI)= 0.82 (0.77, 0.87), p=4.94x10⁻¹⁰) and rs9267280 (OR (95% CI)= 1.32 (1.19, 1.47), 338 339 p=3.48x10⁻⁷).

All rights reserved. No reuse allowed without permission.

340 Cross ancestry equivalent of established risk variants, including the well-known 341 haplotype DRB1*13:01-DQA1*01:03-DQB1*06:03

342 The DRB1*13:01-DQA1*01:03-DQB1*06:03 haplotype is well known to reduce risk of cervical cancer and HPV(+) OPC^{10,11,28}. Notably, the two novel *DRB1* amino acid changes. DRB1 343 37Asn/Ser and DRB1 233Thr, described here for risk of HPV(+) OPCs are within this 344 345 haplotype (Figure 4a). To determine if the haplotype is completely represented by these amino 346 acid changes, we replaced the amino acids with the full haplotype in the risk model for HPV(+) 347 OPC (Figure 4c). Unexpectedly, the effect of HLA-B 67Cys/Ser/Tyr disappeared when 348 including the haplotype, suggesting these are shared risk loci. When all three variants were 349 replaced by the haplotype, the haplotype was independently associated with HPV(+) OPC risk (OR (95% CI)= 0.53 (0.43, 0.63), p_{meta}=1.76x10⁻¹⁰), as described previously¹¹. Importantly, 350 351 model accuracy was highest for the model consisting of the original three amino acid changes 352 compared to the haplotype, suggesting that the specific independent effects of the newly 353 identified DRB1 37Asn/Ser, DRB1 233Thr, and possibly HLA-B 67Cys/Ser/Tyr underlie the 354 effect of the DRB1*13:01-DQA1*01:03-DQB1*06:03 haplotype. The importance of these 355 amino acid changes is highlighted by their allele frequencies across populations, compared to 356 the haplotype (Figure 4d). The allele frequency of the haplotype across genetic ancestries is 357 low and ranges from 3% to 6%, while the frequency of the three amino acids across ancestries 358 is much higher, ranging from 26% to 33%.

The novel rs2523679 variant, which decreases risk of HPV(+) OPC (OR (95% CI) = 0.63 (0.53, 0.75), p_{meta} =2.26x10⁻⁷), tags the established HLA-B*15:01 (r²=0.51) and HLA-B 156Trp (r²=0.51) signals that were previously found in those of European ancestry. Here we show that while the effects of HLA-B*15:01 and HLA-B 156Trp remain specific to European ancestry, rs2523679 confers a similar level of risk for both European and admixed populations, providing a cross-ancestral equivalent of this loci (Figure 4e). Other cross ancestral validated loci are described in Tables S10 and S11.

366 Discussion

Across the GWAS and HLA focused analyses, we identify 29 novel variants associated with risk of HNSCC. Due to increased power compared to previous GWA studies, we identified novel genetic variants including in *TP53 and STING1* and validated known variants in *BRCA2* separately in LA and HPC, two under-studied cancer sites, as well as multiple novel signals in HPC, such as *GDF7*. Novel variants from fine mapping highlight key differences in HLA associations between HPV(+) OPCs, HPV(-) OPCs and OCs. Post-GWAS analyses, including

All rights reserved. No reuse allowed without permission.

373 colocalisation and the use of harmonized individual level risk factor data enabled the 374 investigation of variant function and variant-environment interactions.

375 A key finding was the identification of the low frequency rs78378222 variant located in the 3' 376 UTR of *TP53*. This variant is an eQTL for *TP53* with the variant causing decreased expression 377 in blood and a protective effect against overall HNSCC. This finding supports a previous 378 candidate SNP study in a non-Hispanic white population assessing its effect on HNSCCs (OR=0.44, 95% CI: 0.24,0.79, p=0.008)²⁹. Interestingly, while this variant is protective for 379 HNSCCs and breast cancers³⁰, it increases risk of skin basal cell carcinoma²¹, brain tumours,²¹ 380 colorectal adenocarcinoma²¹, esophageal SCC,³¹ prostate cancers,²¹ and neuroblastoma³². 381 382 Mouse models developed by Deng and colleagues have demonstrated these contrasting effects³⁰. Mice with the variant exhibited reduced tumor formation and increased survival rates 383 384 for breast cancers but showed the opposite trend for gliomas. The authors demonstrated the 385 rs78378222 variant compromises the microRNA (miR)-325 target site but creates a miR-382 386 target site in the p53 mRNA. Both these microRNA molecules downregulate p53 but have 387 differential tissue expressions. miR-325 expression is high in breast tissue meaning the variant 388 p53 can escape the miR-325 downregulation, but brain tissue has high miR-382 expression, 389 meaning the variant p53 has increased downregulation. Future work should investigate the 390 effect of miR-325 regulation of p53 in head and neck tissues of carriers of rs78378222.

391 Two closely linked genetic variants were identified in 5q31, including the missense variant 392 rs1131769 found in the cyclic dinucleotide (CDN) binding domain of TMEM173 gene, of which 393 the resultant STING1 protein detects viral DNA and bacterial CDNs to activate the host 394 immune response in humans. Notably, this variant shows no association with HPV(+) OPC, 395 but a consistent increased risk for all non-HPV cancer types. Both variants also showed 396 evidence of eQTLs for CTNNA1, a gene in which germline genetic variants are known to cause 397 Hereditary Diffuse Gastric Cancer³³.

398 We were able to validate several known HNSCC risk variants and further investigate their 399 interaction with major risk factors. rs11571833 has been linked with lung and upper aerodigestive tract cancers³⁴; here we demonstrate this effect is largest in LA and HPC 400 401 cancers. This variant, found in *BRCA2*, causes a 93 amino-acid deletion including the RAD51 402 binding domain, important in the Fanconi Anaemia Pathway for double strand DNA repair, and 403 is distinct to the highly penetrant familial *BRCA* mutations³⁵. Previous literature suggests smoking is mainly implicated in the mechanism of action of rs11571833.²⁷ However, here we 404 405 provide evidence cross ancestry and separately in the European and Mixed ancestry groups 406 that this variant increases HPV-negative cancer risk with either the exposure of smoking or

All rights reserved. No reuse allowed without permission.

407 drinking, and that there is no effect in never-smoking non-drinkers. This supports the theory that DNA repair to environmental factors is disrupted³⁵ and suggests the crucial DNA damage 408 409 in HNSCC can be contributed to by alcohol use or smoking. In similar analyses, we show the 410 well-known ADH1B variant rs1229984, confers a protective effect for OC which is strongest in 411 non-drinking smokers, suggesting a mechanism through smoking as well as alcohol use. The 412 CHRNA5 variant, rs58365910, was identified as a suggestive association for risk of LA cancer. 413 As expected, this variant only shows an effect in smokers, suggesting that it acts through its known effect on smoking heaviness.³⁶ 414

415 Through HLA fine mapping efforts, we identified 11 novel loci specific to the HLA region, of which eight were separately associated with risk of OC, HPV(+) OPC or HPV(-) OPC. Most of 416 417 the class I loci were found in HLA-B, while most the class II loci were in DRB1. Given the 418 dense, overlapping structure of the HLA region, we also identified functionally equivalent 419 signals at the amino acid, allele, or haplotype level, enabling these data to support a variety 420 of downstream applications requiring functional information.

421 A novel class II haplotype was identified for risk of OC, DRB1*15:01-DQA1*01:02-422 DQB1*06:02. This haplotype has been found to reduce autoantibody development and 423 abnormalities of metabolic traits, such as dysglycemia. As such, this haplotype was found to be protective against progression of type I diabetes (DM)³⁷. The relevance of this finding is 424 425 evidenced by a meta-analysis that found that individuals with DM have a higher risk of 426 developing oral cancer³⁸, potentially related to DM-related metabolic traits such as hypertension and dyslipidemia³⁹. Nevertheless, a link between DM and OC remains 427 428 inconsistent⁴⁰⁻⁴². The OC-specific validated variant, rs4990036, is also associated with a non-HPV infection, varicella zoster⁴³, highlighting that other infections may be important in cancer 429 430 risk. This is especially important considering the oral microbiome as a potential emerging risk 431 factor for oral cavity cancer.

432 The well-known haplotype, DRB1*13:01-DQA1*01:03-DQB1*06:03, has been found to be 433 protective against cervical cancer and HPV(+) OPC, highlighting its role in detecting HPV infection ^{10,11,28}. This haplotype is present at about 5% in the European ancestry and less 434 435 common in other ancestries. We show here that the DRB1*13:01-DQA1*01:03-DQB1*06:03 436 haplotype is represented by the novel three novel amino acid changes identified in this work, 437 DRB1 37Asn/Ser, DRB1 233Thr, and HLA-B 67Cys/Ser/Tyr. Notably however, the amino acid 438 changes themselves more precisely estimate risk of HPV(+) OPC across ancestries and likely 439 drive the effect of the haplotype across ancestries. The higher allele frequencies of the amino 440 acids, ranging from 26% to 33%, allows for better detection of risk for HPV(+) OPC across

populations and might be easier to incorporate into screening strategies at the populationlevel.

The novel intronic rs2523679 variant is a cross-ancestral equivalent of HLA-B*15:01 and HLA-B 156Trp, two previously identified European-specific variants. This novel variant can now be used to evaluate risk of HPV(+) OPC across multiple ancestries, and highlights the importance of including non-European populations, even with limited sample size.

In this work, we were limited by the power from non-European populations, forcing us to combine multiple populations. Although this did provide additional power for discovery, it will have reduced the ability to identify variants specific to certain populations. Where variants were specific to non-European ancestries, we were able to assess these in the different populations but increased sample sizes from more diverse populations should still be seen as a priority in this field.

Although analysing all-site HNSCC can be beneficial, it must be remembered that these cancers are heterogeneous, and the subsite analyses provide a clearer picture of the genetic architecture of the conditions. Where we identify genetic variants in one site, we assess the effect of this variant across all subsites to assess the heterogeneity but despite the increased sample size in this study, there may still be limited power for discovery, especially in the less common subsites such as HPC.

459 In summary, in this HNSCC GWAS which includes diverse populations, we identify 29 novel 460 genetic variants associated with HNSCC and its subsites, including rs78378222 in the TP53 461 3' UTR which confers a 40% reduction in odds of developing overall HNSCC. We expand 462 knowledge of the gene-environment relationship of BRCA2 and ADH1B variants 463 demonstrating their effects act through both smoking and alcohol use. Finally, through 464 analyses focused on the HLA region, we highlight that although HPV(+) OPC, HPV(-) OPC 465 and OC all show GWAS signal at 6p21, each subsite has distinct associations at the variant, 466 amino acid and 4-digit allele level.

467 Data Availability Statement

- The full GWAS summary statistics generated from our meta-analyses will be made publiclyaccessible on (https://gwas.mrcieu.ac.uk/).
- 470 Additional datasets analyzed in this study are accessible through dbGaP471 (https://www.ncbi.nlm.nih.gov/gap/) as follows:
- 472 OncoArray Consortium Lung Cancer Studies (dbGaP Study Accession: phs001273.v4.p2),

- 473 OncoArray: Oral and Pharynx Cancer (dbGaP Study Accession: phs001202.v2.p1),
- 474 National Cancer Institute (NCI) Head and Neck Cancer Study conducted on the
- 475 HumanOmniExpress-12v1.0 array (dbGaP Study Accession: phs001173.v1.p1),
- 476 Genome-Wide Association Study of Oral Cavity, Pharynx, and Larynx Cancers in European,
- 477 North, and South American populations (dbGaP Study Accession: phs002503.v1.p1).
- 478 Data from the UK Biobank and ALSPAC consortium, are available through their respective479 access protocols.
- 480 **Code availability statement**
- 481 This study did not employ any custom code. Instead, it utilized publicly available software tools
- 482 for genetic analyses, which are cited throughout the manuscript and reporting summary.

483 References

- Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of
 Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **71**, 209–249 (2021).
- 487 2. Johnson, D. E. *et al.* Head and neck squamous cell carcinoma. *Nature Reviews*488 *Disease Primers 2020 6:1* 6, 1–22 (2020).
- 489
 489
 3. Lubin, J. H. *et al.* An examination of male and female odds ratios by BMI,
 490
 491
 491
 491
 491
 491
 492
 492
 492
 493
 494
 494
 494
 495
 495
 495
 496
 496
 497
 497
 498
 498
 498
 499
 499
 490
 490
 490
 490
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 492
 492
 492
 493
 494
 494
 494
 494
 494
 494
 495
 495
 496
 496
 497
 498
 498
 498
 499
 498
 499
 499
 499
 490
 490
 490
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 491
 492
 492
 492
 492
 492
 493
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 <li
- 493
 4. Thomas, S. J., Penfold, C. M., Waylen, A. & Ness, A. R. The changing aetiology
 494
 495
 495
 496
 497
 498
 498
 499
 499
 499
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
 490
- 496 5. Hobbs, C. G. L. *et al.* Human papillomavirus and head and neck cancer: a
 497 systematic review and meta-analysis. *Clinical Otolaryngology* **31**, 259–266
 498 (2006).
- 6. Gillison, M. L., Chaturvedi, A. K., Anderson, W. F. & Fakhry, C. Epidemiology of
 Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J *Clin Oncol* 33, 3235–3242 (2015).
- 5027.Chaturvedi, A. K. *et al.* Human papillomavirus and rising oropharyngeal cancer503incidence in the United States. *J Clin Oncol* **29**, 4294–4301 (2011).

5048.Jamieson, L. M. *et al.* Cohort profile: indigenous human papillomavirus and505oropharyngeal squamous cell carcinoma study - a prospective longitudinal506cohort. *BMJ Open* **11**, e046928 (2021).

- 507 9. WHO Classification of Tumours Editorial Board. *Head and Neck Tumours: WHO*508 *Classification of Tumours*. vol. 9 (International Agency for Research on Cancer;
 509 Forthcoming., 2024).
- 51010.Ferreiro-Iglesias, A. *et al.* Germline determinants of humoral immune response511to HPV-16 protect against oropharyngeal cancer. *Nat Commun* **12**, (2021).
- 51211.Lesseur, C. *et al.* Genome-wide association analyses identify new susceptibility513loci for oral cavity and pharyngeal cancer. Nat Genet 48, 1544–1550 (2016).
- 51412.McKay, J. D. *et al.* A Genome-Wide Association Study of Upper Aerodigestive515Tract Cancers Conducted within the INHANCE Consortium. *PLoS Genet* 7,516e1001333 (2011).
- 51713.Lesseur, C. *et al.* Genome-wide association meta-analysis identifies pleiotropic518risk loci for aerodigestive squamous cell cancers. *PLoS Genet* **17**, e1009254519(2021).
- 520 14. Shete, S. *et al.* A Genome-Wide Association Study Identifies Two Novel
 521 Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck.
 522 *Cancer Res* (2020) doi:10.1158/0008-5472.CAN-19-2360.
- 523 15. Elmusrati, A., Wang, J. & Wang, C. Y. Tumor microenvironment and immune 524 evasion in head and neck squamous cell carcinoma. *Int J Oral Sci* **13**, (2021).
- 525 16. Zhang, Z. *et al.* Polymorphisms in the PVT1 Gene and Susceptibility to the Lung
 526 Cancer in a Chinese Northeast Population: a Case-control Study. *J Cancer* 11,
 527 468–478 (2020).
- 52817.Song, N. *et al.* Evaluation of gene-environment interactions for colorectal cancer529susceptibility loci using case-only and case-control designs. *BMC Cancer* **19**, 1–53010 (2019).
- 53118.Lesseur, C. et al. A case-control study of polymorphisms in xenobiotic and532arsenic metabolism genes and arsenic-related bladder cancer in New533Hampshire. Toxicol Lett **210**, 100–106 (2012).
- 53419.Garcia-Closas, M. *et al.* Genome-wide association studies identify four ER535negative-specific breast cancer risk loci. Nat Genet 45, (2013).

| 536 537 | 20. | Eeles, R. A. <i>et al.</i> Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nat Genet</i> 45 , (2013). |
|--------------------------|-----|---|
| 538 539 | 21. | Stacey, S. N. <i>et al.</i> A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nat Genet</i> 43 , 1098–1103 (2011). |
| 540 541 542 | 22. | Zaidi, A. A., Verma, A., Morse, C., Ritchie, M. D. & Mathieson, I. The genetic and phenotypic correlates of mtDNA copy number in a multi-ancestry cohort. <i>HGG Adv</i> 4 , (2023). |
| 543 544 545 | 23. | Hägg, S., Jylhävä, J., Wang, Y., Czene, K. & Grassmann, F. Deciphering the genetic and epidemiological landscape of mitochondrial DNA abundance. <i>Hum Genet</i> 140 , 849–861 (2021). |
| 546 547 548 | 24. | Guo, H., Cao, W., Zhu, Y., Li, T. & Hu, B. A genome-wide cross-cancer meta- analysis highlights the shared genetic links of five solid cancers. <i>Front Microbiol</i> 14 , (2023). |
| 549 550 | 25. | Drobni, P., Näslund, J. & Evander, M. Lactoferrin inhibits human papillomavirus binding and uptake in vitro. <i>Antiviral Res</i> 64 , 63–68 (2004). |
| 551 552 553 | 26. | Bukowska-Ośko, I. <i>et al.</i> Lactoferrin as a Human Genome "Guardian"—An Overall Point of View. <i>International Journal of Molecular Sciences 2022, Vol. 23,</i> <i>Page 5248</i> 23 , 5248 (2022). |
| 554 555 | 27. | Delahaye-Sourdeix, M. <i>et al.</i> A rare truncating BRCA2 variant and genetic susceptibility to upper aerodigestive tract cancer. <i>J Natl Cancer Inst</i> 107 , (2015). |
| 556 557 | 28. | Chen, D. <i>et al.</i> Genome-wide association study of susceptibility loci for cervical cancer. <i>J Natl Cancer Inst</i> 105 , 624–633 (2013). |
| 558 559 560 561 | 29. | Guan, X., Wang, L. E., Liu, Z., Sturgis, E. M. & Wei, Q. Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. <i>J Cell Mol Med</i> 17 , 873–878 (2013). |
| 562 563 564 | 30. | Deng, Q. <i>et al.</i> Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. <i>Nature Communications 2019 10:1</i> 10 , 1–13 (2019). |
| 565 566 567 | 31. | Zhou, L., Yuan, Q. & Yang, M. A functional germline variant in the P53 polyadenylation signal and risk of esophageal squamous cell carcinoma. <i>Gene</i> 506 , 295–297 (2012). |

| 568 | 32. | Diskin, S. J. et al. Rare variants in TP53 and susceptibility to neuroblastoma. J |
|-----|-----|---|
| 569 | | Natl Cancer Inst 106 , (2014). |

- 570 33. Lobo, S. *et al.* Cancer predisposition and germline CTNNA1 variants. *Eur J Med* 571 *Genet* 64, (2021).
- 572 34. Delahaye-Sourdeix, M. *et al.* A rare truncating BRCA2 variant and genetic 573 susceptibility to upper aerodigestive tract cancer. *J Natl Cancer Inst* **107**, (2015).
- 57435.Rafnar, T. *et al.* Association of brca2 k3326* with small cell lung cancer and575squamous cell cancer of the skin. J Natl Cancer Inst **110**, (2018).
- 36. Ware, J. J., Van den bree, M. B. M. & Munafò, M. R. Association of the CHRNA5A3-B4 Gene Cluster With Heaviness of Smoking: A Meta-Analysis. *Nicotine & Tobacco Research* 13, 1167 (2011).
- 57937.Pugliese, A. et al. HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02Haplotype580Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the581Stages of Disease Progression. Diabetes 65, 1109–1119 (2016).
- 58238.Ramos-Garcia, P., Roca-Rodriguez, M. del M., Aguilar-Diosdado, M. &583Gonzalez-Moles, M. A. Diabetes mellitus and oral cancer/oral potentially584malignant disorders: A systematic review and meta-analysis. Oral Dis 27, 404–585421 (2021).
- 58639.Tseng, K. S., Lin, C., Lin, Y. S. & Weng, S. F. Risk of head and neck cancer in587patients with diabetes mellitus: a retrospective cohort study in Taiwan. JAMA588Otolaryngol Head Neck Surg 140, 746–753 (2014).
- 589 40. Zhou, X. H. *et al.* Diabetes, prediabetes and cancer mortality. *Diabetologia* 53, 1867–1876 (2010).
- 59141.Lo, S. F. *et al.* Modest increase in risk of specific types of cancer types in type 2592diabetes mellitus patients. *Int J Cancer* **132**, 182–188 (2013).
- 59342.Stott-Miller, M. *et al.* History of diabetes and risk of head and neck cancer: a594pooled analysis from the international head and neck cancer epidemiology595consortium. Cancer Epidemiol Biomarkers Prev 21, 294–304 (2012).
- 59643.Kachuri, L. *et al.* The landscape of host genetic factors involved in immune597response to common viral infections. Genome Medicine 2020 12:1 12, 1–18598(2020).
- 59944.Hibbert, J., Halec, G., Baaken, D., Waterboer, T. & Brenner, N. Sensitivity and600specificity of human papillomavirus (Hpv) 16 early antigen serology for hpv-

| All rights reserved. No reuse allowed without permission. |
|---|
|---|

| 601 602 | | driven oropharyngeal cancer: A systematic literature review and meta-analysis. <i>Cancers</i> vol. 13 Preprint at https://doi.org/10.3390/cancers13123010 (2021). |
|-------------------|-----|---|
| 603 604 | 45. | Meyer HV. plinkQC: Genotype quality control in genetic association studies. Preprint at https://doi.org/10.5281/zenodo.3934294 (2020). |
| 605 606 | 46. | Chang, C. C. <i>et al.</i> Second-generation PLINK: rising to the challenge of larger and richer datasets. <i>Gigascience</i> 4 , 7 (2015). |
| 607 608 | 47. | Taliun, D. <i>et al.</i> Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. <i>Nature 2021 590:7845</i> 590 , 290–299 (2021). |
| 609 610 | 48. | Das, S. <i>et al.</i> Next-generation genotype imputation service and methods. <i>Nat Genet</i> 48 , 1284–1287 (2016). |
| 611 612 | 49. | Fraser, A. <i>et al.</i> Cohort profile: The avon longitudinal study of parents and children: ALSPAC mothers cohort. <i>Int J Epidemiol</i> 42 , 97–110 (2013). |
| 613 614 615 | 50. | Jones, R. W. <i>et al.</i> A new human genetic resource: a DNA bank established as part of the Avon longitudinal study of pregnancy and childhood (ALSPAC). <i>Eur J Hum Genet</i> 8 , 653–660 (2000). |
| 616 617 | 51. | Manichaikul, A. <i>et al.</i> Robust relationship inference in genome-wide association studies. <i>Bioinformatics</i> 26 , 2867–2873 (2010). |
| 618 619 | 52. | Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in unrelated individuals. <i>Genome Res</i> 19 , 1655–1664 (2009). |
| 620 621 | 53. | 1000 Genomes Project Consortium <i>et al.</i> A global reference for human genetic variation. <i>Nature</i> (2015) doi:10.1038/nature15393. |
| 622 623 624 | 54. | Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. <i>BIOINFORMATICS APPLICATIONS NOTE</i> 26 , 2190–2191 (2010). |
| 625 626 627 | 55. | Luo, Y. <i>et al.</i> A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. doi:10.1038/s41588-021-00935-7. |
| 628 629 | 56. | Okada, Y. <i>et al.</i> Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. <i>Am J Hum Genet</i> 95 , 162–172 (2014). |
| 630 631 | 57. | Yang, J. A. <i>et al.</i> GCTA: A Tool for Genome-wide Complex Trait Analysis. <i>Am J Hum Genet</i> 88 , 76–82 (2011). |

| 632 | 58. | Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating missing |
|-----|-----|---|
| 633 | | heritability for disease from genome-wide association studies. Am J Hum Genet |
| 634 | | 88 , 294–305 (2011). |
| 635 | 59. | Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of |
| 636 | | Genetic Association Studies Using Summary Statistics. <i>PLoS Genet</i> 10 , (2014). |
| 637 | 60. | Võsa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of |
| 638 | | genetic loci and polygenic scores that regulate blood gene expression. Nat |
| 639 | | Genet 53 , 1300–1310 (2021). |
| 640 | 61. | Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across |
| 641 | | human tissues. Science (1979) 369, (2020). |
| 642 | 62. | Liu, M. et al. Association studies of up to 1.2 million individuals yield new insights |
| 643 | | into the genetic etiology of tobacco and alcohol use. Nature Genetics vol. 51 |
| 644 | | Preprint at https://doi.org/10.1038/s41588-018-0307-5 (2019). |
| 645 | | |
| 646 | | |

647 Online Methods

648 Study Design and Populations

649 Individual level data came from 18 studies across 23 countries in Europe, Middle East, North 650 America, South America, and South Asia, and 9 genotyping arrays (Table S1). Informed 651 consent and ethical approval for genotyping was obtained under each individual study. An 652 overall ethical approval for this analysis was obtained from the IARC Ethics Committee (IEC, 653 19-38). Data on demographics (sex, age, country), diagnosis (TNM status, year of diagnosis, 654 ICD code -7th edition), HPV status (HPV16E6 serology, P16 immunohistochemistry (IHC), and HPV DNA in situ hybridisation (ISH)) and self-reported behaviors (smoking status, packyears, 655 656 and drinking status) were collated and harmonized across all study participants. Eligible sites 657 for inclusion consisted of the oral cavity (C00.3, C00.4, C00.5, C00.6, C00.8, C00.9, C02.0-658 C02.9 (except C02.4 and C02.8), C03.0-C03.9, C04.0-C04.9, C05.0-C06 (except C05.1, 659 C05.2)); oropharynx (C01-C01.9, C02.4, C05.1, C05.2, and C09.0–C10.9); hypopharynx 660 (C12.0-C13.0); larynx (C32); and unknown primary site/overlapping/not otherwise specified (NOS) sites (C14, C05.8, C02.8, C76.0). Base of tongue (C01) and tonsils (C09) were 661 662 grouped with oropharynx as these sites are frequently driven by HPV16. For studies with 663 available information on HPV infection for OPC tumors, the HPV status provided by the centre 664 was used (P16 status, HPV DNA ISH, or HPV serology). When information from various 665 methods was available, a positive HPV status was determined by the presence of the HPV16 666 E6 antibody in serology. If serology data were absent, dual positivity of p16 and HPV DNA ISH was classified as HPV positive (HPV(+)), while dual negativity of p16 and HPV DNA ISH was 667 classified as HPV negative (HPV(-)). Any other combinations of test results were considered 668 669 as "not available"⁴⁴.

Nineteen studies were included here with either multi-center case-control, cohort, or clinical trial study designs. Previously generated data was either downloaded from dbGap, requested through controlled access from relevant consortia, or contributed by the study PI and contributed 10,404 cases and 34,596 controls. New genotyping data was generated for 8,669 cases and 4261 controls and were not included in any previous GWAS. All study details, including data sources, dbGap accession numbers and case control distributions across subsites can be found in Table S1.

677 Genotype quality control and imputation

A flow diagram detailing the preparation of the genetic data can be found in the supplementary
 material (Figure S10). Genotypes were generated from nine different genotyping arrays (Table

All rights reserved. No reuse allowed without permission.

680 S1). All newly generated genotype data was called using GenomeStudio (Illumina, 2014). 681 Quality control steps were conducted within each array. All genotype data were converted to 682 genome build 38, using the LiftOver program (https://genome.ucsc.edu/cgi-bin/hgLiftOver) to 683 convert from previous builds. Genotype data was checked and corrected for consistency of 684 strand, positions and reference alleles. Quality control was conducted using the PlinkQC package⁴⁵ in R, utilising PLINK 1.9⁴⁶. Samples were filtered for sex mismatch (males with 685 686 SNP sex <0.8; females with SNP sex >0.2), missingness (>3%), heterozygosity (>3 standard 687 deviations from mean) and cryptic relatedness (identity-by-descent > 0.185). Variants were filtered for genotype missingness (>1%), deviation from Hardy Weinberg equilibrium (p <1x10⁻ 688 689 ⁵) and minor allele count (<20). The number of samples and variants removed at each QC 690 step is provided in Table S2 and Table S13. All arrays were imputed to the TOPMED imputation panel⁴⁷ separately using the TOPMED Imputation server⁴⁸. 691

692 To increase the number of controls comparable to the participants in the HN5000 study, 17,815 693 additional participants (including known related individuals) were included from the Avon 694 Longitudinal Study of Parents and Children (ALSPAC), which had been previously genotyped (Table S1)^{49,50}. To account for potential batch effects between the HN5000 study (Infinium 695 696 Global Screening Array [GSA]) and additional ALSPAC controls (Illumina 550 Quad, Illumina 697 660W Quad), a double imputation approach was applied (Supplementary Note 1). Briefly, GSA 698 HN5000 cases and the additional controls were imputed to the TOPMED reference panel 699 separately as detailed above. Following this step, variants which were (i) genotyped on both arrays, (ii) genotyped on the GSA with high quality imputation (R² score >0.9) on the ALSPAC 700 701 array and, (iii) genotyped on the ALSPAC array with high guality imputation (R^2 score >0.9) on 702 the GSA were selected. These variants were merged across the two arrays, converted to 'best-703 guess' genotypes and then included in a second joint imputation to the TOPMED reference 704 panel. This method allowed high quality imputation of both datasets. To address concerns 705 about batch effects between cases and controls genotyped separately, 405 ALSPAC controls 706 were also genotyped on the GSA alongside the HN5000 cases. This enabled sensitivity 707 analyses to account for potential batch effects.

708 Genetic Ancestry stratification

Following the imputation process, markers from each imputation batch were filtered based on an imputation score of $R^2 > 0.8$ and merged across imputation batch and chromosome. Markers were filtered for a call rate ≥ 0.98 and minor allele frequency (MAF) $\ge 1\%$. The major histocompatibility complex (MHC) region was removed, and the remaining markers were pruned for independent variants using linkage disequilibrium (LD) with a squared correlation

All rights reserved. No reuse allowed without permission.

714 (r^2) threshold of < 0.2. This set of markers (N=697,099) was utilized to compute kinship estimates between Individuals using the KING-robust kinship estimator⁵¹ in PLINK 2.0⁴⁶. The 715 716 KING-robust method is specifically designed to be robust to population structure and 717 admixture. It calculates kinship coefficients without being biased by the fact that certain 718 populations may have different allele frequencies. In addition to the removal of 6,679 known 719 related individuals from the ALSPAC study, a kinship cutoff of > 0.0884 was applied to exclude 720 unexpected duplicates and individuals related at the second degree or closer. This cutoff is 721 based on the geometric mean of the theoretical values for second- and third-degree kinship, 722 as outlined in the manual. Selection of related individuals or duplicates were prioritized based 723 on either disease status (favouring cases over control) or array type (favouring newer arrays 724 over older ones). After this process, 3,441 individuals were excluded from the analysis. The 725 remaining 58,625 individuals were classified into genetic ancestries using supervised 726 ADMIXTURE analysis (ADMIXTURE 1.3⁵²) with 75,164 common markers retained after 727 guality control steps (Figure S11). This assigns a percentage probability for belonging to each 728 of the reference super-populations in the 1000 Genomes Project (N=2,504)⁵³. We assigned 729 individuals to a dominant genetic ancestry if their probability was ≥70% to any reference super-730 population. Of all individuals, 48,029 (83%) had a dominant genetic ancestry while the 731 remainder were classified as admixed. The distribution of individuals with a dominant genetic 732 ancestry was as follows: 80.2% European (EUR), 0.1% Admixed Americans (AMR), 1.2% 733 Africans (AFR), 1.3% South Asians (SAS), and 0.2% East Asians (EAS). The remaining 17% 734 were not able to be classified with a dominant genetic ancestry and were grouped as 735 "admixed". To improve statistical power to detect risk loci across the relatively small sample 736 sizes of non-European genetic ancestries, all five (AMR, AFR, SAS, EAS and admixed) were 737 merged to create a "Mixed" group (n = 11,462) (Figure S12a, S12b). Genome-Wide 738 Association Studies (GWAS) were conducted separately in the European and Mixed ancestry 739 samples and meta-analysed (see later). Principal Component Analysis (PCA) was carried out 740 within each ancestral sample (European and Mixed) to assess population substructure and 741 for covariate adjustment in GWAS (Figure S13). For HLA fine-mapping analyses, a slightly 742 different approach was required due to the region's high LD and highly correlated variants. 743 Additionally, the HLA region is more susceptible to population substructure, making it 744 challenging to identify causal variants that are consistent across ancestries. Therefore, for fine 745 mapping, samples were grouped according to their dominant genetic ancestry (>70%) (EUR, 746 AFR, and SAS) or admixed. Based on the homogeneous clustering identified through PCA 747 (Figure S14), the samples from Iran were separated to Middle Eastern (ME) ancestry. Small 748 size numbers (Case/Control < 50) of genetic ancestries (AMR and EAS) were merged into 749 admixed. For each sample, PCA identified informative principal components (PCs) that 750 showed significant associations (p < 0.05) with case-control status after adjusting for sex and

imputation batch. These informative PCs, along with sex and imputation batch, were includedas model covariates in the GWAS analysis.

753 Association, Meta- and Conditional Analysis

754 Across the 9 arrays and 19 studies, there were several considerations in how to adjust for 755 batch effects. Some studies, such as ARCAGE, were split across different arrays, such as the 756 Oncoarray and AllofUs array. For other studies, such as UKBiobank, several arrays were used 757 (UKBiLEVE and AffymetricUKB) (Table S1). Finally, HN5000 and ALSPAC differed in their 758 imputation as the 'double imputation' method was used. Therefore, a 'Batch' variable was 759 created to represent the combination of studies, arrays and imputation approaches that could 760 contribute to batch effects. To evaluate the potential impact of these different batches in the 761 regression models, we conducted a sensitivity analysis by running GWAS within each batch 762 and assessed heterogeneity using METAL⁵⁴. We excluded markers with a heterogeneity p-763 value $<5x10^{-8}$, resulting in the removal of 137 markers in the European sample GWAS.

764 Association analysis was conducted separately for all sites combined and for each HNSCC 765 subsite in the European and Mixed samples using PLINK. The results were then metaanalysed with METAL⁵⁴ using a fixed effects model to identify cross-ancestral loci. There was 766 767 minimal inflation after adjustment for informative PCs in most analyses (lambda (λ) ranging 768 from 1.00 to 1.03). However, the HPV(+) and HPV(-) OPC analyses for the Mixed group did 769 show evidence of inflation (HPV(+) OPC: λ =1.12; HPV(-) OPC: λ =1.20) (Figure S15). 770 Consequently, rather than a meta-analysis, the GWAS analysis for OPC was conducted only 771 in the European sample with consistency of top SNPs assessed separately in the Mixed 772 sample. For all other subsites, loci that achieved $p < 5x10^{-8}$ in the meta-analysis were referred 773 to as cross-ancestral. This threshold was selected as it is equivalent to a standard Bonferonni 774 correction for one million independent tests. Loci satisfying p<5x10⁻⁸ within each ancestral 775 sample which 1) were not significant in the meta-analysis and 2) showed no attenuation upon 776 conditional analysis of nearby lead cross-ancestral SNPs and therefore considered to be 777 independent from the cross-ancestral SNP, were hereby referred to as ancestral-specific 778 (Table S14). Where these existed in the Mixed ancestry sample, further stratification into the 779 five dominant genetic ancestries was performed. Regional association plots were generated 780 using Locus Zoom (https://my.locuszoom.org/).

781 HLA fine mapping

Variants that were directly genotyped in chromosome 6 were extracted from genotyping dataof all arrays and standardized to hg19 using LiftOver. Due to restrictions in data access from

All rights reserved. No reuse allowed without permission.

784 ALSPAC, additional data from UK Biobank was used to replace ALSPAC for double imputation 785 with HN5000 as described above. Per variant QC was conducted by deduplication of SNP 786 data, strand alignment, removal of palindromic variants (i.e., SNPs with A/T or G/C alleles), 787 removal of poor-quality variants with missingness threshold of 10% and Hardy-Weinberg equilibrium threshold of 1x10⁻¹⁰. Sample QC was conducted after the removal of samples with 788 789 high missingness rates, outlier heterozygosity, discordant sex information, and genetically 790 identical samples. A flow diagram of QC steps for the HLA fine mapping is provided in Figure 791 S16.

792 The HLA region (Chromosome 6:28Mb-34Mb) was imputed for SNPs and classical HLA class 793 I and II alleles using the Michigan imputation server with the most recent HLA Multi-ethnic 794 reference panel (Four-digit Multi-ethnic HLA v2)⁵⁵. Only high-guality SNPs, alleles or aminoacid residues were included in the analysis (imputation $r^2 > 0.95$). The final set of imputed 795 796 variants used in association analyses were of high quality; 91% of the variants and 71% of the 797 less common variants (MAF < 0.05) had imputation $R^2 \ge 0.95$. HLA-wide association analysis was conducted controlling for sex, informative PCs, and imputation batch (described above), 798 799 and meta-analyzed with a random effect model using PLINK⁴⁶ to identify cross-ancestral 800 variants. Any genetic ancestries with fewer than 50 samples were excluded from meta-801 analyses due to power. Stepwise conditional analysis was conducted to identify independent 802 variants within each ancestry where variants with the lowest p-value after each round were 803 added to the subsequent model and the analysis was repeated until no further variants met 804 the significance threshold. As HLA fine mapping was conducted independently from GWAS, a 805 probability threshold was set to 2.4×10^{-6} . This was based on the total number of imputed HLA 806 variants (0.05/20,762), which included SNPs, amino acid variants, and classical HLA alleles 807 after quality control as described previously ⁵⁶.

808 To identify haplotypes associated with risk within each subsite that were linked to the top novel 809 variants identified from fine mapping, the haplo.stats package v.1.9.5.1 in R was applied to 810 identify combinations of HLA 4-digit alleles within each population. The haplo.em and 811 haplo.glm algorithms identified haplotype candidates in each population with a minimum 812 haplotype frequency threshold set at 0.01 in comparison to the most common haplotype within the ancestry. Haplotype candidates that were in high LD ($r^2 > 0.8$) with variants from fine 813 814 mapping were then tested for association with risk using the meta-analysis approach to 815 determine if they conferred similar risk compared to their variant counterparts.

816 **Testing for Independence and functional equivalents of lead variants**

All rights reserved. No reuse allowed without permission.

Variants identified in each HNSCC subsite analysis from the GWAS, and fine mapping were compared across subsites to evaluate whether they were linked or independent. This was also performed to define variants that were novel compared to previously reported signals and to determine overlapping signals between cross-ancestral and population-specific variants. LD was measured by r^2 using PLINK 1.9⁴⁶ within the overall dataset. If LD>0.3, then conditional analysis was performed to evaluate if the significance of the variant of interest attenuated to lower than 2.4x10⁻⁶. If both criteria were met, variants were considered to be dependent.

824 To determine functional equivalents of the variants identified through fine mapping, amino acid changes, alleles and haplotypes that were in moderate to high LD (r²>0.5) with lead novel 825 826 variants were further evaluated. Effect sizes and significance levels were compared when 827 replacing the lead variant with the related variant in the fully adjusted cross-ancestral model. 828 Bayesian Information Criterion (BIC) were then evaluated to compare the model fit of the 829 original model with the lead variants identified from fine mapping to the model with the related 830 variant replacing the original lead variant. Every permutation of variants was considered to 831 determine if one variant could replace by another and still provide the same information as the 832 original lead variant.

833 Stratified analyses

834 For each independent top hit identified in GWAS and HLA fine mapping, the analysis was 835 repeated, stratified by sex, smoking status, drinking status, geographic region, and within all 836 cancer subsites separately. The effects across strata were assessed for heterogeneity using 837 x^2 -based Q test (Cochran's Q test) using R (v4.1.2). Further stratification for specific variants related to smoking and alcohol was conducted in non-HPV related cancers. This assessed 838 effects in never-smoking non-drinkers, smoking non-drinkers, never-smoking drinkers and 839 840 ever-smoking drinkers to assess the independence of these risk factors where data was 841 available. Results were presented in forest plots (Figures S7, S9).

842 Heritability and genetic correlation

SNP based heritability was estimated in the European and Mixed ancestry samples using the Genome-based restricted maximum likelihood (GREML) method in GCTA⁵⁷. Imputed genetic data was used, variants with MAF<0.01 and Hardy Weinberg equilibrium p <0.05 were removed, as suggested for case-control data in Lee *et al.* 2011⁵⁸. Univariate GREML was used to estimate heritability and was transformed onto the liability scale using global prevalence estimates from GLOBOCAN¹. Heritability estimates in the Mixed ancestry sample are not

All rights reserved. No reuse allowed without permission.

presented in the main manuscript due to the heterogeneous nature of these samples whichmake estimates of heritability unreliable. These are provided in Table S5 for completeness.

851 Colocalisation of GWAS and eQTL mapping

852 Colocalisation of genetic associations between all identified top hit variants (from GWAS analyses and fine mapping) and their gene expression and related traits was calculated using 853 default LDs and a window size of ± 75 kb using the COLOC package⁵⁹. All colocalisation 854 analyses were conducted using HNSCC data of European ancestry. Expression quantitative 855 trait loci (eQTLs) in whole blood were obtained from the eQTLGen Consortium⁶⁰ due to its role 856 857 in immune response and systemic inflammation. eQTLs in esophagus and lung tissue were sourced from the Genotype-Tissue Expression (GTEx) project (v8)⁶¹, given their anatomical 858 859 proximity and shared risk factors, such as tobacco and alcohol exposure. In the analyses, we considered eQTLs coinciding with genomic loci identified in this study at $p < 3.9 \times 10^{-10}$ in whole 860 blood data; p< 2.5x10⁻⁷ in tissue data to be considered as significant). Summary statistics from 861 862 GWAS for smoking and alcohol consumption behaviors were sourced from the GWAS & Sequencing Consortium on Alcohol and Nicotine Use (GSCAN)⁶². The analysis considers the 863 posterior probability of colocalisation for a single shared variant responsible for the 864 865 associations in both traits (posterior probability for hypothesis 4 (PP4)), values over 0.7 were 866 considered strong evidence of colocalisation. Where the lead variant was not available in the 867 LD reference panel required for COLOC, the variant with the highest LD was used instead.

868 **Technical validation**

For the technical validation of the imputed *TP53* variant, we utilized a Taqman assay to genotype this specific variant in a subset of samples from the Central and Eastern European Study (CEE) and ARCAGE studies. Individuals removed from the GWAS in QC steps or those with technical issues during the Taqman assays, e.g. failure to amplify, were removed resulting in 2,370 samples where consistency could be assessed. Overall concordance and nonreference discordance were calculated.

875 HEADSpAcE Consortium Member Acknowledgements

Adam R¹, Agudo A², Alibhai S³, AlWaheidi SF⁴, Angel Pavon M², Anwar N⁵, Arantes 876 P⁶, Arguello L⁷, Avello Y⁸, Avondet L¹, Baldión-Elorza AM⁸, Batista Daniel C⁹, Beraldi 877 B¹⁰, Berenstein B¹¹, Bernal P¹², Bernardino Rodrigues N¹³, Bilic Zimmermann J², Botta 878 MG⁶, Bouvard L⁴, Brenes J², Brenner N¹⁴, Brentisci C¹⁵, Burtica C⁸, Cabañas ML¹⁶, 879 Cantor E¹⁷, Carvalho RS¹⁸, Carvalho A L¹⁹, Chiusa L²⁰, Chopard P⁴, Chundriger Q²¹, 880 Clavero O², Costa I²², Creaney G²³, Cuffini C²⁴, Dias TC¹⁸, Duccini de Souza E¹⁰, 881 durant I C²⁵, Escallón A²⁶, Fernandes G⁶, Fervers B²⁷, Fiano V²⁸, Firme Figueira F¹³, 882 Furbino Villefort R¹³, Gangemi M¹⁵, Garzino-Demo P²⁹, Gholipour M³⁰, Giglio R¹¹, 883 Goulart MA³¹, Graça Sant'Anna J⁹, Grega M³², Gregório Có A⁹, Guasch A², Hakim 884 JA²⁶, Hayes DN³³, Homero de Sá Santos M¹⁰, Hurley K³⁴, Insfran M³⁵, Iorio GC³⁶, 885 Iqbaluddin Siddiqui M³⁷, Johannsen J³⁸, Kaňa M³⁹, Klussmann J³⁸, Legal E⁴⁰, Lenzi 886 J¹⁰, Luiz Dias F²², Lyra González I⁴¹, Machado Zorzaneli W⁹, Mai Rocha R¹⁰, Maños 887 M², Marinho de Abreu P⁹, Marzban M^{42,43}, McCaul J⁴⁴, McMahon AD³¹, Mena C⁴⁰, 888 Mendonça EF⁴⁵, Mendoza L³⁵, Meza L³⁵, Michels B¹⁴, Mineiro MS⁴⁶, Moccia C²⁸, 889 Mongelos P³⁵, Montealegre-Páez AL⁴⁷, Morey Cortes F², Muñoz A⁴⁸, Ness A³⁴, Neves 890 AB⁶. Oliva M². Oliveira J⁴⁹. Ortiz H⁷. Ortiz J⁴⁰. Osorio M⁴⁰. Ospina V¹⁷. Ostellino O⁵⁰. 891 892 Palau M⁸, Paterson C⁵¹, Paytubi Casabona S², Pecorari G²⁹, Pereira DM⁵², Pérol O²⁷, Pervez S²¹, Pomata A¹⁶, Popovic M²⁸, Poveda A⁴⁷, Prado CP⁶, Prager KM¹⁴, Ramieri 893 G²⁹, Rasul S³, Rego JN⁵³, Reis RM¹⁸, Renard H⁴, Ricardi U³⁶, Riva G²⁹, Rodilla F², 894 Rodriguez I⁵⁴, Rodríguez MI³⁵, Ross A³¹, Roux P⁵⁵, Saeed Ali T⁵⁶, Saintigny P⁵⁷, 895 Santivañez J J²⁶, Scapultampo-Neto C⁵⁸, Segovia J¹⁷, Sena A¹⁰, Serrano R⁴⁰, Sharma 896 S³⁸, Siefer O³⁸, Smart S⁵⁹, Sorroche BP¹⁸, Sosa C¹⁶, Souza JD⁶⁰, Stura A¹⁵, Thomas 897 S³⁴, Torres O⁶¹, Tous S², Ucross G¹², Valenzuela A³⁵, Vasconcelos de Podestá J¹⁰, 898 Whitmarsh A³⁴, Wright S⁶² 899

900

¹H&N cancer Department, Universidad de Buenos Aires, Ciudad Autonoma de Buenos
 Aires, Argentina, ²Catalan Institute of Oncology (ICO), Barcelona, Spain, ³Department
 of Surgery, Dental Hygiene Program, Aga Khan University Hospital, Karachi, Pakistan,
 ⁴Genomic Epidemiology Branch, International Agency for Research on cancer
 (IARC/WHO), Lyon, France, ⁵Faculty of Science and Technology, University of Central
 Punjab, Lahore, Pakistan, ⁶Group of Epidemiology and Statistics on Cancer, A.C.

907 Camargo Cancer Center, Sao Paolo, Brazil, ⁷Servicio de Cabeza y Cuello, Instituto 908 Nacional del Cáncer, Ministerio de Salud Pública y Bienestar Social, Capiatá, 909 Paraguay, ⁸Pathology and Laboratory Department, Fundación SantaFe de Bogotá, 910 Bogotá, Colombia, ⁹Postgraduate Program in Biotechnology, Universidade Federal do 911 Espirito Santo, Vitoria, Brazil, ¹⁰Head and Neck Surgery Division, Associação Feminina de Educação e Combateao Câncer(AFECC), Hospital Santa Rita de Cássia, 912 913 Vitoria, Brazil, ¹¹H&N cancer Department, Institute of Oncology Angel H. Roffo, University of Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 914 915 ¹²Department of Radiology, Division of Nuclear Medicine, Fundación SantaFe de Bogotá, Bogotá, Colombia, ¹³Department of Pathology, Universidade Federal do 916 Espirito Santo, Vitoria, Brazil, ¹⁴Division of Infections and Cancer Epidemiology, 917 German Cancer Research Center (DKFZ), Heidelberg, Germany, ¹⁵Department of 918 919 Medical Sciences, Cancer Epidemiology Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy, ¹⁶Departamento de Anatomía Patológica, Instituto Nacional del 920 921 Cáncer, Ministerio de Salud Pública y Bienestar Social, Capiatá, Paraguay, 922 ¹⁷Oncology Deparment, Fundación SantaFe de Bogotá, Bogotá, Colombia, 923 ¹⁸Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil, 924 ¹⁹Department of Head and Neck Surgery, Barretos Cancer Hospital, Barretos, Brazil, 925 ²⁰Pathology Unit, AOU Città della Salute e della Scienza di Torino, Turin, Italy, 926 ²¹Department of Pathology and Laboratory Medicine, Section of Histopathology, Aga 927 Khan University Hospital, Karachi, Pakistan, ²²INCA, Rio de Janeiro, Brazil, ²³School 928 of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, United Kingdom, ²⁴Universidad Nacional de Cordoba, Cordoba, Argentina, ²⁵A.C Camargo Cancer 929 Center, São Paulo, Brazil, ²⁶Department of Surgery, Head and Neck Division, 930 931 Fundación SantaFe de Bogotá, Bogotá, Colombia, ²⁷Department Cancer 932 Environnement, Centre Léon Bérard, Lyon, France, ²⁸Department of Medical Sciences, Cancer Epidemiology Unit, University of Turin, Turin, Italy, ²⁹Department of 933 Surgical Sciences, University of Turin, Turin, Italy, ³⁰Metabolic Disorders Research 934 Center, Golestan University of Medical Sciences, Gorgan, Iran, ³¹School of Medicine, 935 Dentistry and Nursing, University of Glasgow, Glasgow, United Kingdom, 936 ³²Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles 937 University and Motol University Hospital, University Hospital in Motol, Prague, Czech 938 Republic, ³³Department of Genetics, Genomics and Informatics, University of 939 940 Tennessee Health Science Center, Memphis, USA, ³⁴Bristol Dental School, University

941 of Bristol, Bristol, United Kingdom, ³⁵Salud Pública, Instituto de Investigaiones en Ciencias de la Salud (IICS), Universidad Nacional de Asunción (UNA), San Lorenzo, 942 Paraguay, ³⁶Department of Oncology, University of Turin, Turin, Italy, ³⁷Department of 943 944 Surgery, Section of E.N.T. Aga Khan University Hospital, Karachi, Pakistan, 945 ³⁸Department of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, Cologne, Germany, ³⁹Department of Otorhinolaryngology and Head and Neck 946 947 Surgery, University Hospital in Motol, Prague, Czech Republic, ⁴⁰Cátedra Otorrinonaringología, Hospital de Clínicas, Facultad de Ciencias 948 Médicas. Universidad Nacional de Asunción, San Lorenzo, Paraguay, ⁴¹Servicio de Oncología 949 Clínica Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay, ⁴²The 950 Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical 951 Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran, 952 ⁴³Statistics Genetic Lab, QIMR, Berghofer Medical Research Institute, Brisbane, 953 Australia, ⁴⁴Department of Oral and Maxillofacial/Head and Neck Surgery, NHS 954 Greater Glasgow and Clyde, Glasgow, United Kingdom, ⁴⁵Hospital Câncer Araújo 955 Jorge, Goiânia, Brazil, ⁴⁶Hospital Câncer Araújo jorge, Goiânia, Brazil, ⁴⁷Faculty of 956 Medicine. El Bosque University, Bogotá, Colombia, ⁴⁸Oncology Department, Division 957 958 of Radiotherapy, Fundación SantaFe de Bogotá, Bogotá, Colombia, ⁴⁹Goiânia Cancer Registry (BR), Goiânia, Brazil, ⁵⁰Department of Oncology, Division of Medical 959 960 Oncology, AOU Città della Salute e della Scienza di Torino, Turin, Italy, ⁵¹Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, United 961 962 Kingdom, ⁵²Radiation Oncology Department, Institute of Oncology Angel H. Roffo, University of Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵³Clinical 963 964 Research Center, Associação Feminina de Educação e Combateao Câncer(AFECC), Hospital Santa Rita de Cássia, Vitoria, Brazil, ⁵⁴Laboratorio de Anatomía Patológica, 965 966 Hospital de Clínicas, Facultad de Ciencias Médicas, Universidad Nacional de 967 Asunción, San Lorenzo, Paraguay, ⁵⁵Department of Surgery, Centre Léon Bérard, Lyon, France, ⁵⁶School of Nursing and Midwifery, Aga Khan University Hospital, 968 Karachi, Pakistan, ⁵⁷Centre Léon Bérard, Lyon, France, ⁵⁸Pathology and Molecular 969 970 Diagnostics Service, Barretos Cancer Hospital, Barretos, Brazil, ⁵⁹University of Glasgow, Glasgow, United Kingdom, ⁶⁰Epidemiology and Statistics Group, Research 971 972 Center, A.C Camargo Cancer Center, São Paulo, Brazil, ⁶¹Radiology Department, Fundación SantaFe de Bogotá, Bogotá, Colombia, ⁶²Institute of Cancer Sciences, 973 974 University of Glasgow, Glasgow, United Kingdom.

975



Figure 1. Novel loci identified for HNSCC. a) Circular Manhattan plots showing novel risk loci identified in this study. Red labels indicate the cytogenetic locations of novel signals identified in meta-analyses for all sites combined or subsite-specific. Blue labels represent novel loci identified in the European group only, and green labels indicate novel loci identified in the Mixed group only. Red lines mark the threshold for genome-wide significance ($p = 5x10^{-8}$). b) Circular Manhattan plots from the GWAS analyses of HPV(+) and HPV(-) oropharyngeal cancer. Separate Manhattan plots for each group can be found in Supplementary Figure 1.



Figure 2. Regional and Colocalization Analysis of *TP53* **and** *STING1* **Variants.** a) Regional plot of the 3' UTR variant rs78378222 in *TP53* at chromosome 17p13. The x-axis represents chromosomal location, while the y-axis displays the –log10 p-value. The dotted line marks the genome-wide significance threshold of 5×10^{-8} . Single nucleotide polymorphisms (SNPs) are color-coded according to their linkage disequilibrium (r²) with rs78378222. b) Z-Z locus plot showing rs78378222, the lead variant, is associated with reduced TP53 expression in whole blood, with a high PP4 score of 99%. c) The cytogenetic location of rs78378222, along with its sequence and allele change, is shown at the chromosomal level. The variant overlaps with multiple predicted microRNA binding sites. d) Regional plot of rs28419191 (intergenic) and rs1131769 (*STING1*) at 5q31 from the oral cavity (OC) meta-analysis (r² = 0.93). e) Z-Z locus plot showing colocalization of rs28419191 and rs1131769 with *CTNNA1* expression in whole blood, both with a PP4 score of 99%.



Figure 3. Gene-environment interactions with alcohol and smoking. Effect estimates for a) rs11571833 (*BRCA2*) b) rs1229984 (*ADH1B*) and c) rs58365910 (*CHRNA5*) stratified by smoking and drinking (Never smoker-Never drinker, Smoker Only, Drinker Only, and Ever smoker-Ever drinker) from the meta-analysis, and within European, and Mixed groups. Only the odds ratios, p-value and p-heterogeneity (p-het) for the meta-analysis are shown here.



Figure 4. Cross-ancestry HLA risk loci of HPV(+) OPC. a) Manhattan plots showing all independent lead variants for risk of HPV(+) OPC. Variants highlighted under significance threshold reached significance in later rounds; only the plot from the first round of stepwise analysis is shown here. Novel variants are orange; known variants are grey. The horizontal red line reflects the HLA significance threshold (p < 2.4×10^{-6}). DRB1 37Asn/Ser, DRB1 233Thr, are within DRB1*13:01-DQA1*01:03-DQB1*06:03 while HLA-B67Cys/Ser/Try was associated with the haplotype. b) Out of the five interchangeable amino acid residues in LD with DRB1 233Thr with \triangle BIC ±2, DRB1 12Lys and DRB1 10Glu/Gln are in the HLA-DR binding pocket. c) Model accuracy and risk estimates of amino acid residues and haplotypes. Model 1: identified from fine-mapping, used as the baseline reference model; Model 2: replaces DRB1 37Asn/Ser, DRB1 233Thr with the haplotype, effect of HLA-B 67Cys/Ser/Try disappears; Model 3: All 3 amino acids replaced with haplotype. d) Allele frequencies of DRB1*13:01-DQA1*01:03-DQB1*06:03 and of having all three amino acid residues by ancestry. e) The HLA-B 156Trp amino acid change and the HLA-B 15:01 allele are specific to European ancestry, but rs2523679 variant which is in LD with both, has a cross-ancestral effect.



Figure 5. Novel HLA risk loci for HPV(-) oropharynx and oral cavity cancer. Manhattan plots display all independent lead variants of risk for each HNSCC subsite. Novel variants are highlighted in red; known variants are in grey. The horizontal red line reflects the HLA significance threshold (p < 2.4×10^{-6}) a) HPV(-) oropharynx: The lead SNP, b) rs1131212, causes an amino acid change from Gln to His at residue 94 located in the HLA-B protein binding pocket (PDB ID: 2BVP). This variant is in LD (r²=1) with 70Asn/Ser. The right panel shows the comparable risk effects of the two related signals. The known SNP, c) rs1264813, is in high LD (r²=0.77) with HLA-A*24 allele and shows comparable risk effects shown in right panel. d) Oral cavity: The lead SNP, rs9268925, is highly correlated with a novel risk haplotype, DRB1*15:01-DQA1*01:02-DQB1*06:02, and has a similar risk effect, as shown in the right panel. Model accuracy difference (\triangle BIC) between original model in presence of all independent lead variants and the model replacing the lead variant with related amino acid residue, allele or haplotype, lower than 2 confer equivalent risk.

| Population | Subsite | rsID | Mapped/N earest Gene | CHR | BP (GRCh38) | Cytogeneti c Position | Major Allele | Effect Allele | EAF | OR (95%CI) | p-value |
|---------------------------------|------------|--------------------------|----------------------------|-----|-------------|--------------------------|-----------------|------------------|-------|--------------------|------------------------|
| | | rs61817953 | PIK3C2B | 1 | 204493484 | 1q32 | G | А | - | 0.90 (0.87, 0.93) | 1.17x10 ⁻⁸ |
| | All sites | rs6679311 | MDM4 | 1 | 204590548 | 1q32 | С | Т | - | 1.11 (1.07, 1.14) | 1.25x10 ⁻¹⁰ |
| | | rs1131769 | STING1 | 5 | 139478334 | 5q31 | С | Т | - | 1.13 (1.09, 1.18) | 2.38x09 ⁻⁰⁹ |
| | combined | rs7334543 | BRCA2 | 13 | 32399139 | 13q13 | А | G | - | 0.91 (0.88, 0.94) | 2.39x08 ⁻⁰⁸ |
| | | rs78378222ª | TP53 | 17 | 7668434 | 17p13 | Т | G | - | 0.62 (0.52, 0.73) | 2.16x08 ⁻⁰⁸ |
| | | rs10419397 | ANKLE1 | 19 | 17280519 | 19p13 | G | А | | 1.13 (1.10, 1.17) | 1.21x14 ⁻¹⁴ |
| Mata Analysia | | rs28419191 | ECSCR | 5 | 139465014 | 5q31 | С | Т | - | 1.23 (1.15, 1.31) | 3.16x10 ⁻¹⁰ |
| Meta-Analysis | OC | rs67351073 | ZGPAT | 20 | 63704213 | 20q13 | GA | G | - | 0.78 (0.72, 0.85) | 4.45x08 ⁻⁰⁸ |
| | | rs577454702 ^a | MAPK1 | 22 | 21778123 | 22q11 | А | С | - | 2.60 (1.86, 3.65) | 2.53x08 ⁻⁰⁸ |
| | LA | rs55831773 | ATP1B2 | 17 | 7655719 | 17p13 | С | Т | - | 1.21 (1.13, 1.29) | 5.1x09 ⁻⁰⁹ |
| | LA | rs10419397 | ANKLE1 | 19 | 17280519 | 19p13 | G | А | - | 1.18 (1.10, 1.26) | 4.33x08 ⁻⁰⁸ |
| | HPC | rs138707495 | GDF7 | 2 | 20677150 | 2p24 | Т | TA | - | 3.06 (2.07, 4.53) | 2.33x08 ⁻⁰⁸ |
| | | rs77750788 | IGSF9B | 11 | 133936692 | 11q25 | G | А | - | 2.07 (1.61, 2.68) | 2.03x08 ⁻⁰⁸ |
| | | rs181194133ª | OPCML | 11 | 132728232 | 11q25 | G | А | - | 3.44 (2.24, 5.31) | 2.09x08 ⁻⁰⁸ |
| European | HPC | rs181777026 | TENM4 | 11 | 81037815 | 11q14 | С | Т | 0.012 | 2.81 (1.94, 4.05) | 3.78x08 ⁻⁰⁸ |
| Ancestry GWAS | HPV(-) OPC | rs112726671 | VDR | 12 | 47926100 | 12q13 | А | G | 0.016 | 2.28 (1.70, 3.07) | 4.03x08 ⁻⁰⁸ |
| | HPV(+) OPC | rs1520483 | LTF | 3 | 46468719 | 3p21 | С | Т | 0.400 | 1.23 (1.14, 1.32) | 2.19x08 ⁻⁰⁸ |
| Mixed Ancestry Group GWAS | LA | rs200410709 | STXBP6 | 14 | 25417834 | 14q12 | CT | С | 0.013 | 3.38 (2.26, 5.07) | 3.57x09 ⁻⁰⁹ |
| | HPC | rs150899739 | SASH1 | 6 | 148061934 | 6q24 | G | А | 0.008 | 5.84 (3.17, 10.76) | 1.47x08 ⁻⁰⁸ |

Table 1. Summary of Novel Genetic Variants Identified in European and Mixed Groups Through GWAS and Meta-Analysis

Novel variants identified in meta-analysis and by group across subsites. Full list of significant variants can be found in Supplementary Table 3. CHR = Chromosome; BP = Base-pair position; EAF = Effect allele frequency; OR = Odds ratio; OC = Oral cavity; LA = Larynx; HPC = Hypopharynx; OPC = Oropharynx.

a These variants were only identified in European GWAS and were not present in the mixed group, as their minor allele frequency was below the 0.05% threshold determined in our analyses.

| Populati on | Subsite | Variant | Gene | Position (hg19) | Locus; Cytoband | Impact | Refª | Effect Allele ^a | OR (95% CI) | p-value ^b |
|-------------------|-----------------------|--------------------|-----------|-----------------|--------------------|-------------------------------|------|-------------------------------|------------------|------------------------|
| Meta- Analysis | All sites | Chr6:33046667 | HLA-DPB1 | Chr6:33046667 | class II | intron | С | Т | 1.11 (1.07,1.14) | 1.32x10 ⁻⁸ |
| | combined | rs28360051 | PSORS1C3 | Chr6:31142261 | | intron | G | А | 1.23 (1.14,1.34) | 1.91x10 ⁻⁷ |
| | HPV(-) OPC | rs1131212 | HLA-B | Chr6:31324526 | class I | Gln94His | С | G | 1.33 (1.19,1.49) | 5.33x10 ⁻⁷ |
| | HPV(+) OPC | DRB1 37Asn/Ser | HLA-DRB1 | Chr6:32552051 | class II | Amino acid change | Ab | Pr | 0.68 (0.63,0.73) | 3.22x10 ⁻²³ |
| | | rs4143334 | ZDHHC20P2 | Chr6:31348200 | class I | Non coding transcript exon | А | G | 1.89 (1.51,2.35) | 1.91x10 ⁻⁸ |
| | | DRB1 233Thr | HLA-DRB1 | Chr6:32548048 | class II | Amino acid change | Ab | Pr | 1.27 (1.17,1.38) | 7.15x10 ⁻⁹ |
| | | B 67Cys/Ser/Tyr | HLA-B | Chr6:31324536 | class I | Amino acid change | Ab | Pr | 0.81 (0.74,0.88) | 1.33x10 ⁻⁰⁶ |
| Admixed | All sites combined | rs1536036 | ITPR3 | Chr6:33632014 | | Intron | А | G | 0.85 (0.80,0.91) | 8.42x10 ⁻⁷ |
| European | OC | DRB1 74Ala/Leu/Del | HLA-DRB1 | Chr6:32552625 | class II | Amino acid change | Ab | Pr | 0.82 (0.77,0.87) | 4.94x10 ⁻¹⁰ |
| | | rs9267280 | MICB-DT | Chr6:31457633 | class I | Intron | G | А | 1.32 (1.19,1.47) | 3.48x10 ⁻⁷ |
| | HPV(+) OPC | HLA-B*51:01 | HLA-B | Chr6:31321767 | class I | Amino acid change | Ab | Pr | 1.9 (1.55,2.31) | 3.6x10 ⁻¹⁰ |

Table 2. Summary of Novel Genetic Variants Identified Across Ancestry-Specific and Meta-Analysis of HLA-fine mapping in all sites combined and subsite specific

Novel variants identified in meta-analysis and ancestry specific groups shown here. No novel variants were identified within Middle Eastern, African and South Asian populations. Full list of variants in this region can be found in Supplementary Table 10. All variants were tested for independence, which was defined by linkage disequilibrium (R2) < 0.3 and Bonferroni threshold of P > 10-6 when conditioning on variants from other subsites or with previously identified variants. Further details can be found in Supplementary Tables 8 and 9

a Ref/Al allele is in binary marker format (Ab = Absent, Pr = Present) of classical HLA alleles, amino acid residue, HLA intragenic, insertion/deletions. (see: https://imputationserver.readthedocs.io/en/latest/pipeline)

b meta-analysis Pvalue of the final model including all significant independent variants adjusted by sex, imputation batch and PCs HLA significance level = 2.4×10^{-6} considering all variants in chr6